Mesenchymal Stem Cell Therapy to Reduce the Neurological Deficit of Chronic Ischemic Stroke Patients: A Systematic Review
Embedded Files
Suryanita
Faculty of Medicine, University of Jember, Jember, Indonesia
Muhammad Ihwan Narwanto
Faculty of Medicine, University of Jember, Jember, Indonesia
Yuli Hermansyah
Faculty of Medicine, University of Jember, Jember, Indonesia
Cholis Abrori
Faculty of Medicine, University of Jember, Jember, Indonesia
Novan Krisno Adji
Faculty of Medicine, University of Jember, Jember, Indonesia
DOI: https://doi.org/10.19184/jembermedicaljournal.v3i2.943
Abstract
Current ischemic and hemorrhagic stroke treatments are limited by a narrow golden period and lack of regenerative benefits, so stem cell therapy emerges as an ideal candidate for functional recovery in stroke patients. Stem cell therapy, still being studied, is expected to repair ischemic areas damaged by stroke to restore their physiological functions and reduce neurological deficits in chronic stroke patients. This study aimed to determine the therapeutic efficacy of MSCs in reducing neurological deficits in chronic ischemic stroke patients. We conducted a systematic review. We searched PubMed, Cochrane Library, Science Direct, and Springer Link from inception until December 2022 for cohort studies dealing with mesenchymal stem cell therapy for patients with ischemic stroke. The citation-searching method in this study collected 1,038 articles using the advanced searching method and 8 articles using the citation-searching method, bringing the total number of articles to 1,046. Determination of synonyms using MeSH to facilitate the making of keywords. All articles found are then included on the Rayyan QCRI website, which can assist reviewers in selecting journals. The number of articles used in this study were 2 English-language research articles discussing the potential of MSCs therapy to improve nerve function in chronic ischemic stroke patients with NIHSS scores in the last 10 years (2012-2022) with a cohort study design and had passed the ROBINS-I quality and risk of bias assessment with a low risk of bias. The exclusion criteria used were articles with systematic reviews and meta-analyses and articles that were not accessible in full text. Based on the results of a systematic review study conducted, the conclusion that can be drawn is that MSCs therapy has proven effective in reducing neurological deficits in chronic ischemic stroke patients in terms of the decreased NIHSS score.
Keyword: Mesenchymal stem cell, chronic ischemic stroke, neurological deficit, NIHSS
REFERENCE
Chamorro, Á., A. Meisel, A. M. Planas, X. Urra, D. Van De Beek, and R. Veltkamp. 2012. The Immunology of Acute Stroke. Nature Reviews Neurology. July 2012.
Chiu, T. L., R. Baskaran, S. T. Tsai, C. Y. Huang, M. H. Chuang, W. S. Syu, H. J. Harn, Y. C. Lin, C. H. Chen, P. C. Huang, Y. F. Wang, C. H. Chuang, P. C. Lin, and S. Z. Lin. 2022. Intracerebral transplantation of autologous adipose-derived stem cells for chronic ischemic stroke: a phase i study. Journal of Tissue Engineering and Regenerative Medicine. 16(1):3–13.
Feigin, V. L., M. Brainin, B. Norrving, S. Martins, R. L. Sacco, W. Hacke, M. Fisher, J. Pandian, and P. Lindsay. 2022. World Stroke Organization (WSO): Global Stroke Fact Sheet 2022. International Journal of Stroke. January 1, 2022.
Fu, X., G. Liu, A. Halim, Y. Ju, Q. Luo, and G. Song. 2019. Cells mesenchymal stem cell migration and tissue repair
Go, A. S., D. Mozaffarian, V. L. Roger, E. J. Benjamin, J. D. Berry, M. J. Blaha, S. Dai, E. S. Ford, C. S. Fox, S. Franco, H. J. Fullerton, C. Gillespie, S. M. Hailpern, J. A. Heit, V. J. Howard, M. D. Huffman, S. E. Judd, B. M. Kissela, S. J. Kittner, D. T. Lackland, J. H. Lichtman, L. D. Lisabeth, R. H. Mackey, D. J. Magid, G. M. Marcus, A. Marelli, D. B. Matchar, D. K. McGuire, E. R. Mohler, C. S. Moy, M. E. Mussolino, R. W. Neumar, G. Nichol, D. K. Pandey, N. P. Paynter, M. J. Reeves, P. D. Sorlie, J. Stein, A. Towfighi, T. N. Turan, S. S. Virani, N. D. Wong, D. Woo, and M. B. Turner. 2014. Heart Disease and Stroke Statistics - 2014 Update: A Report from the American Heart Association. Circulation. January 21, 2014.
Hess, D. C., L. R. Wechsler, W. M. Clark, S. I. Savitz, G. A. Ford, D. Chiu, D. R. Yavagal, K. Uchino, D. S. Liebeskind, A. P. Auchus, S. Sen, C. A. Sila, J. D. Vest, and R. W. Mays. 2017. Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (masters): a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Neurology. 16(5):360–368.
Huang, L. and L. Zhang. 2019. Neural Stem Cell Therapies and Hypoxic-Ischemic Brain Injury. Progress in Neurobiology. February 1, 2019.
Kawabori, M., H. Shichinohe, S. Kuroda, and K. Houkin. 2020. Clinical Trials of Stem Cell Therapy for Cerebral Ischemic Stroke. International Journal of Molecular Sciences. October 1, 2020.
Kuriakose, D. and Z. Xiao. 2020. Pathophysiology and Treatment of Stroke: Present Status and Future Perspectives. International Journal of Molecular Sciences. October 2, 2020.
Levy, M. L., J. R. Crawford, N. Dib, L. Verkh, N. Tankovich, and S. C. Cramer. 2019. Phase i/ii study of safety and preliminary efficacy of intravenous allogeneic mesenchymal stem cells in chronic stroke. Stroke. 50(10):2835–2841.
Manley, N. C. and G. K. Steinberg. 2012. Tracking Stem Cells for Cellular Therapy in Stroke
Murphy, S. J. and D. J. Werring. 2020. Stroke: Causes and Clinical Features. Medicine (United Kingdom). September 1, 2020.
Musiał-Wysocka, A., M. Kot, and M. Majka. tanpa tahun. The pros and cons of mesenchymal stem cell-based therapies
Mutiarasari, D., B. I. Kesehatan, M.-K. Komunitas, and F. Kedokteran. 2019. ISCHEMIC STROKE: SYMPTOMS, RISK FACTORS, AND PREVENTION
Permana, A. T., N. S. Suroto, M. A. Parenrengi, A. H. Bajamal, P. Lestari, and A. Al Fauzi. 2022. Current update on stroke ischemic management. International Journal of Health & Medical Sciences. 5(1):122–128.
Steinberg, G. K., D. Kondziolka, L. R. Wechsler, L. Dade Lunsford, A. S. Kim, J. N. Johnson, D. Bates, G. Poggio, C. Case, M. McGrogan, E. W. Yankee, and N. E. Schwartz. 2019. Two-year safety and clinical outcomes in chronic ischemic stroke patients after implantation of modified bone marrow-derived mesenchymal stem cells (sb623): a phase 1/2a study. Journal of Neurosurgery. 131(5):1462–1472.
Wang, F., H. Tang, J. Zhu, and J. H. Zhang. 2018. Transplanting mesenchymal stem cells for treatment of ischemic stroke. Cell Transplantation. 27(12):1825–1834.
Yang, Y., Y.-Z. Shi, N. Zhang, S. Wang, G. S. Ungvari, C. H. Ng, Y.-L. Wang, X.-Q. Zhao, Y.-J. Wang, C.-X. Wang, and Y.-T. Xiang. 2016. The disability rate of 5-year post-stroke and its correlation factors: a national survey in china
Zhang, R., J. Yu, N. Zhang, W. Li, J. Wang, G. Cai, Y. Chen, Y. Yang, and Z. Liu. 2021. Bone marrow mesenchymal stem cells transfer in patients with st-segment elevation myocardial infarction: single-blind, multicenter, randomized controlled trial. Stem Cell Research and Therapy. 12(1)
Zhang, Y ;, N ; Dong, H ; Hong, J ; Qi, S ; Zhang, J Wang, Yuchen Zhang, Naijun Dong, Huanle Hong, Jingxuan Qi, Shibo Zhang, and Jiao Wang. 2022. Citation: mesenchymal stem cells: therapeutic mechanisms for stroke.
Published
November 20 , 2024
Issue
Vol. 3 No. 2 (2024)
Section
Review Article
License
Copyright (c) 2025 Jember Medical Journal
Under License of Creative Commons Attribution ShareAlike 4.0 International Generic (CC BY-SA 4.0).
Page updated
Report abuse